| Abstract: | Beta2‐adrenergic receptor (β2‐AR) is a G‐protein‐coupled adrenergic receptor family member, whose clinical significance has been extensively investigated in lung, cardiovascular and muscular diseases, but its role in kidney biology remains understudied. In this review, we discuss some of the recent studies, where the effect of agonist/antagonist‐mediated activation/inhibition of β2‐AR on disease pathogenesis process was studied, and highlighted the role of β2‐AR in kidney biology. The expression of β2‐AR has been noted in many kidney subunits including proximal tubules, glomeruli and podocytes. In vivo studies have shown that in cultured proximal tubules β2‐AR is involved in Na‐ATPase activity and transcellular Na‐transport through protein kinase‐C activation; whereas in cultured podocytes, it was associated with depolarization of the membrane. The animal studies further revealed that β2‐AR activation by short‐acting β2 agonists attenuated monocyte activation, pro‐inflammatory and pro‐fibrotic responses through β‐arrestin2 dependent NF‐kB inactivation in diabetic kidney disease; in contrast, activation by long‐acting β2 agonists restored mitochondrial and renal function in the acute kidney injury mice models through PGC‐1α dependent mitochondrial biogenesis. In conclusion, the activation of β2‐AR may present a rapidly developing therapeutic target for renal diseases. |
